Albumin-bound Paclitaxel Combined With Cisplatin Versus Docetaxel Combined With Cisplatin Induced Chemotherapy in Advanced Head and Neck Squamous Tummor

Inclusion Criteria:

* Inclusion criteria:

  1. Age ≥18 years old, male or female;
  2. Subjects had squamous cell carcinoma of the head and neck confirmed by histrohistology or cytology;
  3. CLINICAL STAGE III OR IV WITHOUT DISTANT METASTASES (AJCC 8th)
  4. Patients who have not previously received initial treatment with chemotherapy or radiation;
  5. KPS acuity 70;
  6. Normal bone marrow reserve function and normal liver and kidney function;
  7. Expected survival time ≥3 months;
  8. Subjects of child-bearing age must agree to use effective contraceptive measures during the study period; The serum or urine pregnancy test must be negative for women of childbearing age 72 hours before the start of chemotherapy;
  9. Subjects have good compliance, can carry out treatment and follow-up, and voluntarily abide by the regulations of this study;
  10. Subjects voluntarily sign the informed consent.

Exclusion Criteria:

* Exclusion criteria:

  1. Patients with distant metastasis;
  2. The presence of uncontrolled serious medical diseases, such as combined with serious medical diseases, including serious heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, uncontrolled infection, active peptic ulcer, etc.;
  3. The presence of dementia, altered mental status or any mental illness that would prevent understanding or giving informed consent or filling out questionnaires;
  4. Subjects with grade ≥2 peripheral neuropathy according to CTCAE V5.0;
  5. A history of allergy or hypersensitivity to any therapeutic ingredient;
  6. Suffered from malignant tumors other than squamous cell carcinoma of the head and neck in the past 5 years, except adequately treated basal cell or squamous cell skin cancer, local prostate cancer after radical surgery, and ductal carcinoma in situ after radical surgery;
  7. Abnormal results of physical and laboratory tests:

     A) Hematologic abnormalities are defined as:

     I) Absolute count of neutrophils (ANC) : \< 1.5×109 / L; Ii) Platelet (PLT) count: \< 100×109/L; Iii) Hemoglobin (Hb) level \< 90g/L;

     B) Abnormal liver function is defined as:

     I) Total bilirubin (TBIL) level: 1.5 times of the upper limit of normal value of \> (ULN); Ii) AST and ALT levels of \>ULN were 2.5 times, and BBB\>N was 5 times if liver metastasis was present;

     C) Definition of abnormal renal function:

     1.5 times of serum creatinine \> ULN, or the calculated creatinine clearance rate \< 50ml/min;
  8. Patients who need to be treated with other anti-tumor drugs;
  9. Has received any other investigational drug therapy or participated in another interventional clinical trial within 30 days prior to screening;
  10. The researcher considers it unsuitable for inclusion;
  11. Pregnant or lactating women.